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Abstract 
Complement activity in turkey serum was examined by using inhibitors or activators of mammalian 
complement. Hemolytic test systems using sheep red blood cells sensitized with specific antibody 
(SSRBC) and horse red blood cells (HRBC) were developed to measure residual complement activity of 
turkey sera treated with the various inhibitors or activators. Lysis of SSRBC was blocked by treatment with 
6-mM EDTA, 10-mM ethylene glycol-bis-βaminoethylether N,N,N′,N′ tetraacetic acid (EGTA), and 
carrageenan. In contrast, lysis of HRBC was blocked by 6-mM EDTA, but not by 10-mM EGTA or 
carrageenan. Addition of magnesium to EGTA-chelated serum facilitated the lysis of HRBC but not the 
lysis of SSRBC. Treatment of serum with zymosan at 1 mg/mL and inulin at 5 mg/mL depleted hemolytic 
activity against both SSRBC and HRBC, suggesting depletion of components common to both pathways. 
Differences in the hemolytic activities of sera against SSRBC and HRBC after treatment with the various 
complement inhibitors and activators demonstrate the presence of two complement pathways in turkeys. 
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ABSTRACT Complement activity in turkey serum was examined by using inhibitors or activators of 
mammalian complement. Hemolytic test systems using sheep red blood cells sensitized with specific 
antibody (SSRBC) and horse red blood cells (HRBC) were developed to measure residual complement 
activity of turkey sera treated with the various inhibitors or activators. Lysis of SSRBC was blocked by 
treatment with 6-mAf EDTA, 10-mAf ethylene glycol-bis-Paminoethylether N,N,N',N' tetraacetic acid 
(EOT A), and carrageenan. In contrast, lysis of HRBC was blocked by 6-mAf EDTA, but not by 10-mAf EGTA 
or carrageenan. Addition of magnesium to EGTA-chelated serum facilitated the lysis of HRBC but not the 
lysis of SSRBC. Treatment of serum with zymosan at 1 mg/mL and inulin at 5 mg/mL depleted hemolytic 
activity against both SSRBC and HRBC, suggesting depletion of components common to both pathways. 
Differences in the hemolytic activities of sera against SSRBC and HRBC after treatment with the various 
complement inhibitors and activators demonstrate the presence of two complement pathways in turkeys. 
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INTRODUCTION 
The humoral complement system, a group 
of serum proteins, is involved in mediation of 
inflammation and host defense against bacte-
ria, parasites, and viruses (Frank, 1979). Two 
pathways of complement activation are recog-
nized in mammals, namely the classical and 
alternative pathways. The classical pathway is 
activated by specific antibody, or by certain 
polymeric substances such as heparin, prota-
mine, carrageenan, and lipid A of gram-
negative bacteria (Cooper, 1985). In contrast, 
the alternative pathway is not activated by 
specific antibody but by the covalent binding 
of the third component (C3) to aggregated 
immunoglobulins or complex polysaccharides 
such as zymosan, inulin, and lipopolysaccha-
ride of gram-negative bacteria (Muller-Eber-
hard and Schreiber, 1980). The classical and 
alternative pathways converge with the cleav-
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age of C3 as the common pathway, culminat-
ing in the formation of a membrane attack 
complex. Insertion of this complex into biolog-
ical membranes results in increased per-
meability and subsequent cell lysis (Muller-
Eberhard, 1986). 
Research on chicken complement strongly 
suggests the presence of both classical and 
alternative complement pathways analogous to 
the mammalian complement pathways. The 
lysis of sheep red blood cells sensitized with 
antibody is evidence of classical complement 
activity in chickens (Ohta et al., 1984). Several 
viruses, as well as xenogenic red blood cells 
are known to activate the chicken and quail 
alternative complement pathways (Yoshikawa 
et al, 1978; Koch et al, 1982; Ohta et al., 
1984, 1986). Additional support for classical 
and alternative complement activities is shown 
by the specific isolation of complement com-
ponents from both pathways (Kai et al., 1983; 
Koch et al., 1983; Lee, 1984; Yonemasu and 
Sasaki, 1986). 
Basic information on the classical or alter-
native pathways of turkey complement is not 
available. The mean hemolytic titer of serum 
from 6-wk-old turkeys was reported to be 1:25 
using the lysis of sensitized sheep red blood 
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cells as an indicator system (Skeeles et ai, 
1980). This titer gives a baseline measure for 
complement activity in turkeys. The objectives 
of this research were to investigate the 
presence of classical and alternative comple-
ment pathways in turkeys, and to determine 
concentrations of the various complement 
inhibitors or activators that result in depletion 
of one or both pathways of turkey complement 
activity. 
MATERIALS AND METHODS 
Turkey Serum. Blood was collected from 
commercial adult Nicholas strain turkeys (n = 
25) and allowed to clot at room temperature 
for 1 h and then at 4 C for 1 h. Serum was 
harvested, pooled, and divided into 10-mL 
aliquots. All serum was frozen at -70 C until 
assayed. 
Red Blood Cells. Sheep red blood cells 
(SRBC) and horse red blood cells (HRBC) 
were collected separately, and each was mixed 
with equal volumes of Alsever's solution 
(.114-Af glucose, .072-M NaCl, 2.6-mAf citric 
acid, 27.2-mAf sodium citrate). Red blood cells 
were maintained in Alsever's solution for 1 wk 
prior to use to stabilize the cells. Red blood 
cells were washed twice in phosphate-buffered 
saline, pH 7.2, a third time in gelatin veronal 
buffer (GVB++) containing ,15-mAf CaCl2 and 
.5-mM MgCl2, pH 7.2 (Gewurz and Suyehira, 
1980), and then resuspended in GVB++. The 
HRBC were standardized to 7 x 107 cells/mL 
for use in the hemolytic assay. The SRBC 
were sensitized with specific antibody by 
incubating a 1% SRBC suspension with an 
equal volume of 1:200 turkey anti-SRBC 
antibody at 37 C for 30 min. The SRBC 
sensitized with specific antibody (SSRBC) 
were pelleted, resuspended in GVB++, and 
standardized to a concentration of 1.4 x 108 
cells/mL for use in the hemolytic assay. 
Hemolytic Complement Assays. The hemo-
lytic activity of sera was determined using a 
round-bottom microtiter test plate system. 
Two-fold serial dilutions of test sera (50 \xL/ 
well) were mixed with equal volumes of red 
blood cell suspensions (7 x 107 HRBC/mL or 
1.4 x 108 SSRBC/mL). Control wells contain-
ing 25 |xL of red blood cell suspensions were 
included in the assay to form a pellet 
representing 50% lysis. Plates were incubated 
at 37 C for 1 h (SSRBC) or 2 h (HRBC) as 
previously described (Ohta et ai, 1984). 
Microtiter test plates were then centrifuged to 
pellet unlysed cells. The dilution of serum 
causing a 50% decrease in the red blood cell 
pellet was noted, and the hemolytic titer was 
reported as the reciprocal of that dilution, 
transformed to log2. 
Adsorption of Natural Antibody to Horse 
Red Blood Cells from Turkey Serum. In order 
to determine whether HRBC were lysed by the 
antibody-dependent classical pathway or anti-
body-independent alternative pathway, turkey 
serum was adsorbed with HRBC and then 
hemolytic activity was tested. Turkey serum (1 
mL) was mixed with .25 mL of packed HRBC 
at 4 C for 15 min. Horse red blood cells were 
removed by centrifugation (1,000 rpm, 10 min) 
and the adsorption was repeated. The superna-
tant was collected after the second adsorption 
and tested for hemolytic activity. 
Chelation of Divalent Cations. The EDTA 
and ethylene glycol-bis-paminoethylether 
N,N,N',N' tetraacetic acid (EGTA) compounds 
were prepared as A-M stock solutions. Turkey 
serum (1 mL) was chelated by the addition of 
various concentrations of EDTA or EGTA. All 
samples were brought to a final volume of 1.1 
mL using veronal-buffered saline without 
calcium and magnesium, and examined for 
hemolytic activity. 
Treatment of Turkey Serum with Comple-
ment Activators. Various concentrations of 
zymosan (Sigma Chemical Co., St. Louis, 
MO) and inulin (from chicory root; Sigma) 
were mixed with 1 mL of turkey serum. 
Samples were incubated for 30 min at 37 C, 
centrifuged (2,000 rpm, 30 min, 4 C) and 
supernatants tested for hemolytic activity. 
Various concentrations of carrageenan (Type 
IV, Lambda; Sigma) in .5-mL volumes were 
added to .5 mL of turkey serum. Samples were 
mixed at 4 C for 20 min and then centrifuged 
(2,500 rpm, 20 min). Supernatants were 
collected and tested for hemolytic activity. 
Statistical Analysis. All treatments of serum 
were performed in quadruplicate, and the 
complement titer was determined for each 
treatment. For the analysis of data, individual 
complement titers were transformed to log2, 
and the mean log titer for each serum 
treatment was calculated. Differences between 
serum treatments were examined by least 
squares analysis using the SAS general linear 
models program (Snedecor and Cochran, 
1967). 
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FIGURE 1. Residual hemolytic activity against sheep 
red blood cells sensitized with specific antibody (SSRBC) 
or horse red blood cells (HRBC) after chelation of calcium 
and magnesium ions from turkey serum by EDTA or 
ethylene glycol-bis-paminoethylether N,N,N',N' tetraacetic 
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FIGURE 3. Depletion of hemolytic activity against 
sensitized sheep red blood cells (SSRBC) and horse red 
blood cells (HRBC) by zymosan treatment of turkey 
serum. Data points represent the mean log2 titer of four 
samples. 
RESULTS 
Adsorption of turkey serum with HRBC 
had little effect on hemolytic activity (P>.05). 
Mean hemolytic titers of nonadsorbed and 
adsorbed sera were 5.17 and 4.87, respectively. 
The influence of calcium and magnesium 
ions on the complement activity of turkey 
serum is shown in Figure 1. Chelation of 
calcium and magnesium ions by EDTA at a 
final concentration of 6 mAf blocked hemolytic 
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FIGURE 2. Influence of additional magnesium ions on 
hemolytic activity of normal turkey serum and ethylene 
glycol-bis-Paminoethylether N,N,N',N' tetraacetic acid 
(EGTA)-chelated turkey serum. Data points represent the 
mean log2 titer of four samples. SSRBC = Sensitized sheep 
red blood cells; HRBC = horse red blood cells. 
activity against both SSRBC and HRBC. 
Chelation of calcium ions by EGTA at a final 
concentration of 10 mAf blocked hemolytic 
activity against SSRBC, but did not block all 
hemolytic activity against HRBC. The hemo-
lytic titer against HRBC decreased from 5.17 
for normal serum to 2.96 for serum chelated 
with 10-mAf EGTA. Addition of magnesium 
ions to serum treated with 10-mM EGTA 
restored hemolytic activity against HRBC to 
normal control values (Figure 2). Although 
hemolytic activity against SSRBC was in-
creased by the addition of magnesium ions, 
titers did not reach normal control values. The 
results of addition of magnesium to normal 
turkey serum indicated that hemolytic activity 
against either SSRBC or HRBC was not 
significandy affected. 
Treatment of turkey serum with zymosan or 
inulin depleted hemolytic activity against both 
SSRBC and HRBC as shown in Figures 3 and 
4, respectively. However, turkey complement 
was more sensitive to zymosan than to inulin. 
Whereas zymosan at only 1 mg/mL serum 
abolished hemolytic activity, at least 5 mg 
inulin/mL serum was required to abolish 
hemolytic activity. The effect of carrageenan 
treatment on turkey complement activity is 
shown in Figure 5. With increasing concentra-
tions of carrageenan, hemolytic activity against 
SSRBC decreased, whereas hemolytic activity 
against HRBC was not significantly affected. 
The hemolytic titers of normal serum and 
carrageenan-treated serum (1.5 mg of carragee-
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FIGURE 4. Depletion of hemolytic activity against 
sensitized sheep red blood cells (SSRBC) and horse red 
blood cells (HRBC) by inulin treatment of turkey serum. 
Data points represent the mean log2 titer of four samples. 
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FIGURE 5. Depletion of hemolytic activity against 
sensitized sheep red blood cells (SSRBC) and horse red 
blood cells (HRBC) by carrageenan treatment of turkey 
serum. Data points represent the mean log2 titer of four 
samples. 
nan/.5 mL serum) against HRBC were 4.75 
and 4.25, respectively. 
DISCUSSION 
The results of this study indicate that two 
complement pathways exist in turkeys. Lysis 
of HRBC by turkey complement is mediated 
through an antibody-independent pathway, as 
similarly described for chickens (Ohta et al., 
1984). A common procedure used to separate 
alternative pathway activation from classical 
pathway activation is differential chelation of 
calcium and magnesium ions by EDTA or 
EGTA. Both calcium and magnesium ions are 
strongly chelated by EDTA, whereas only 
calcium ions are chelated efficiently by EGTA. 
Hence, EDTA inhibits both complement path-
ways, and EGTA inhibits only the classical 
complement pathway (Fine et al., 1972). 
Treatment of turkey serum with EGTA did not 
inhibit all hemolytic activity against HRBC, 
therefore suggesting that lysis of HRBC is via 
the alternative complement pathway. 
In contrast, lysis of SSRBC probably occurs 
through activation of the classical complement 
pathway. Evidence for activation of the classi-
cal complement pathway by SSRBC is two-
fold. Firstly, both EDTA and EGTA, chelators 
of calcium ions, blocked the hemolytic activity 
against SSRBC. These chelators inhibit the 
mammalian classical pathway (Marney and 
Des Prez, 1969; Fine et al., 1972). Secondly, 
carrageenan, which is known to precipitate the 
first component of the classical complement 
pathway (Borsos et al., 1965), depleted hemo-
lytic activity against SSRBC, but not HRBC. 
The results obtained from carrageenan treat-
ment of turkey serum also suggest that lysis of 
HRBC does not occur through the classical 
pathway. 
Zymosan and inulin activate the alternative 
complement pathway of mammals (Marney 
and Des Prez, 1969; Fine et al., 1972; 
Schenkein and Ruddy, 1981). In this study, 
depletion of hemolytic activity against both 
SSRBC and HRBC was observed after zymo-
san and inulin treatments of turkey serum. This 
would suggest depletion of a component(s) 
common to both complement pathways, for 
example components of the terminal mem-
brane attack complex. The terminal comple-
ment pathway in avian species has not been 
characterized. Zymosan and inulin treatments 
of turkey serum suggest that a common 
complement pathway arises from the classical 
and alternative pathways, as similarly de-
scribed for the mammalian system (Muller-
Eberhard, 1986). 
Application of assays used in the study of 
mammalian complement has facilitated charac-
terization of complement activity in turkeys. 
The present study shows convincing evidence 
that turkey complement may be activated 
through two pathways, these being the analogs 
of the mammalian classical and alternative 
complement pathways. Lysis of SSRBC occurs 
through an antibody-dependent pathway, 
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which requires calcium and magnesium ions 
for efficient functioning. In contrast, the 
pathway effecting lysis of HRBC is antibody-
independent and requires only magnesium ions 
for efficient functioning. Hence, hemolytic 
activity against SSRBC and HRBC, respec-
tively, represents the classical and alternative 
complement pathways of turkeys. 
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